FindTrial
Sign In

The study for clinical significance and mechanism of soluble CD22, which serves as a potential marker of B-cell activation, in surgical infection

The study for clinical significance and mechanism of soluble CD22, which serves as a potential marker of B-cell activation, in surgical infection

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-RCC-14004598
Enrollment
Unknown
Registered
2014-05-02
Start date
2014-05-05
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgical Infection

Interventions

Infection Group:peripheral blood sample was collectd from each patient and then analysed by ELISA
Control Group:peripheral blood sample was collectd from each patient and then analysed by ELISA

Sponsors

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Individuals with active infection, which caused by various reasons; 2. Individuals with one of the following signs: (1) infectious fever; (2) increased total leucocyte; (3) increased neutral granulocyte or lymphocyte; (4) other symptoms or signs associated with infection.

Exclusion criteria

Exclusion criteria: 1. Individuals undergoing corticosteroid treatment; 2. Individuals undergoing blood transfusion; 3. Individuals undergoing radiotherapy or chemotherapy.

Design outcomes

Primary

MeasureTime frame
Soluble CD2;—

Countries

China

Contacts

Public ContactChen Zhonghua

Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

zc104@medmail.com.cn+86 13908634460

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026